Skip to main content
. 2021 Jan 25;41(2):e00473-20. doi: 10.1128/MCB.00473-20

FIG 8.

FIG 8

Concurrent synthetic lethality. Schematic depicting the concept of concurrent synthetic lethality. NRF2 target genes are able to bioactivate both mitomycin C, to generate the potent DNA-damaging agent MMC*, and 17-AAG, to generate the proteotoxic stress-inducing HSP90 inhibitor 17-AAGH2. The parallel NRF2-dependent metabolism of prodrugs which target distinct cell death pathways increases the specificity and toxicity toward tumor cells with aberrant KEAP1-NRF2 pathway activation.